Welcome
Support Centre
07 August 2008 
Current Controlled Trials - Clinical Trials
Trial registration
Unique identification scheme
International databases
home  |   my details  |   ISRCTN Register  |   mRCT  |   UKCTG  |   links  |   information  |   news
Introduction
English introduction Introduction en français Deutsche einleitung
Introducción española Introduzione in italiano
 
Find trials
active registers
UKCTG
mental health register
archived registers
all registers
tips on searching
 
Registration
submit trials
 
Information
about mRCT
mRCT FAQs
data items
memorandum
contributors

DISCLAIMER
The site should not be used to diagnose or treat a health problem. Please consult your doctor.
Terms & conditions

DUPLICATION
Your search result may contain a number of different records for the same trial. This occurs when the same trial is listed in more than one register.

[ ...Back to search results ] [ Print-friendly version ]
A Phase III study of Radical Radiotherapy with or without Gemcitabine in Patients with T1-2 N0-1 M0 Non-Small Cell Lung Cancer (NSCLC)
Source of recordUK Clinical Trials Gateway
ISRCTNISRCTN61727489
Date ISRCTN assigned15/10/2002
Local reference number(s)GRIN
Public titleA Phase III study of Radical Radiotherapy with or without Gemcitabine in Patients with T1-2 N0-1 M0 Non-Small Cell Lung Cancer (NSCLC)
Scientific title
AcronymN/A
Disease/condition/study domainLung (non-small cell)
Study hypothesisNot provided at time of registration
Design/methodologyRandomised controlled trial
Research ethics reviewNot provided at time of registration
Countries of trialUnited Kingdom
Participants - inclusion criteria1. Histological or cytological diagnosis of T1-2 N0-1 M0 NSCLC in patients deemed unfit for resection in the opinion of the thoracic surgeon
2. No prior chemotherapy or radiotherapy for the treatment of NSCLC
3. Performance status 0-2 on the Zubrod scale 4. Estimated life expectance at least 12 weeks
5. <10% weight loss in the year preceding randomisation
6. Patient compliance and geographic proximity allowing adequate follow-up
7. Adequate bone marrow reserve
8. Adequate respiratory function
9. Radiologically measurable or non-measurable lesion
10. Aged at least 18 years
11. Written informed consent
12. Effective contraception (where appropriate) during and for at least 3 months following the trial
Participants - exclusion criteriaNot provided at time of registration
Patient information material
Anticipated end date31/12/2005
Status of trialCompleted
Target number of participantsNot provided at time of registration
InterventionsPatients will be randomised to:
1. Radiotherapy (55 Gy 2.75 Gy 5 days/week over 4 weeks OR 60 Gy over 6 weeks with daily fractions of 2 Gy)
2. Gemcitabine (100 mg/m2 IV over 30 min, 2-4 h prior to radiotherapy) plus radiotherapy
Primary outcome measure(s)Not provided at time of registration
Secondary outcome measure(s)Not provided at time of registration
Sources of fundingEducational grant from Lilly Oncology to University of Edinburgh
Sponsor nameUniversity of Edinburgh
Sponsor detailsThe University of Edinburgh
Old College
South Bridge
Edinburgh
United Kingdom
EH8 9YL
Sponsor telephone+44 (0)131 650 1000
Sponsor fax+44 (0)131 650 2147
Sponsor emailcommunications.office@ed.ac.uk
Sponsor websitehttp://www.ed.ac.uk
Contact nameDr - -
Contact detailsUKCCCR Register Co-ordinator
MRC Clinical Trials Unit
222 Euston Road
London
United Kingdom
NW1 2DA
Contact telephone+44 (0) 20 7670 4723
Contact fax+44 (0) 20 7670 4818
Contact emailregister@ctu.mrc.ac.uk
More informationFor more up-to-date information please go to the ISRCTN link below.
Link to record in ISRCTN RegisterISRCTN61727489
Date last extracted from ISRCTN register17/04/2008
Submit your trial protocol Top studies in medical research Submit to Trials journal
terms & conditions | privacy statement | © Current Controlled Trials Ltd


BioMed Central